Sarah Cannon Joins Early Breast Cancer Detection Study

NASHVILLE, Tenn.–(BUSINESS WIRE)–Sarah
Cannon
, the Cancer Institute of HCA Healthcare, announced today that
several of its affiliated programs will participate in a new study,
called STRIVE, which focuses on developing a test for early breast
cancer detection. The STRIVE Study is designed to determine if a blood
test can complement mammography screenings by identifying genetic
material arising from tumors to help discover breast cancer at its
earliest stages.

“By participating in this exciting research effort, women in our
communities will help scientists in their efforts to develop a test that
is intended to enhance our ability to detect cancer at earlier and more
treatable stages,” said Dax
Kurbegov, MD
, principal investigator of the STRIVE Study at Sarah
Cannon and Vice President and Physician-in-Chief of Clinical Programs
for Sarah Cannon. “The study is designed to help identify tiny fragments
of genetic material that may signal the presence of breast cancer, and
may help guide healthcare decisions by providing more information and
reducing uncertainty.”

The study, sponsored by GRAIL, Inc., is seeking to enroll 120,000 women
across participating sites. Women who volunteer to participate will
provide a blood sample and complete a short questionnaire at the time of
their regular screening mammogram. In addition, participants will be
followed and their health records will be monitored for up to five years
for new cancer diagnoses.

“Over the last decade, we have begun to better understand the critical
role that genetic information plays in how we diagnose and treat cancer,
but the way in which we apply such insights into early cancer detection
has been limited,” said Howard
A. “Skip” Burris III, MD
, President of Clinical Operations and Chief
Medical Officer at Sarah Cannon. “By participating in this large
clinical research study, we are excited to explore the role that
blood-based testing may play to assist in early cancer detection and how
it may provide an even greater benefit to patients.”

The study will be offered to women undergoing screening mammograms at
the following Sarah Cannon locations: TriStar
Summit Medical Center
and TriStar
Centennial Medical Center
in Tennessee; Centerpoint
Medical Center
and Menorah
Medical Center
in Kansas/Missouri; and Henrico
Doctors’ Hospital
and Johnston-Willis
Hospital
in Virginia. New sites are expected to open for enrollment
in additional locations.

For more information on the STRIVE Study, to see the list of
participating sites or to learn if you might be eligible to join, women
can visit JoinSTRIVE.com,
email STRIVE@sarahcannon.com
or call 1-833-I-STRIVE (833-478-7483).

About Sarah Cannon

Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated
cancer services with convenient access to cutting-edge therapies for
those facing cancer in communities across the United States and United
Kingdom. Sarah Cannon’s cancer programs include individualized patient
navigation provided by oncology-trained nurses, more than 1,000 stem
cell transplants performed annually throughout the Sarah Cannon Blood
Cancer Network, hundreds of clinical trials, and molecular profiling
capabilities. Through its services, Sarah Cannon is providing
state-of-the-art cancer care close to home for hundreds of thousands of
patients, a number unmatched by any single cancer center. To learn more
about Sarah Cannon, visit sarahcannon.com.

About GRAIL

GRAIL, Inc. is a life sciences company whose mission is to detect cancer
early when it can be cured. GRAIL is using the power of high-intensity
sequencing, population-scale clinical trials, and state of the art
Computer Science and Data Science to enhance the scientific
understanding of cancer biology and develop blood tests for early-stage
cancer detection. The company’s funding was led by ARCH Venture Partners
and includes Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers
Squibb, Celgene, Decheng Capital, GV, Illumina, Johnson & Johnson
Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent,
Varian Medical Systems, and other financial partners. For more
information, please visit www.grail.com.

Contacts

Sarah Cannon
Samantha Maxwell
Samantha.maxwell@sarahcannon.com
or
Anna
Walker
Anna.walker@sarahcannon.com
or
For
GRAIL, Inc.
Charlotte Arnold
carnold@grailbio.com